Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.01, read 2026-11-03
Ethical does not pass the values gate
Price59.29 USD
Fair value79.75
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-30Read Markup58.29+1.7% to today ✓Accumulation gives way to Markup first Markup read since October
2026-10-28Read Accumulation56.20+5.5% to today ✓Markup gives way to Accumulation with results news in the headlines
2026-10-22Read Markup56.20+5.5% to today ✓Distribution gives way to Markup after a 5% rise in 8 weeks
2026-08-26Read Distribution53.33+11.2% to today Markup gives way to Distribution first Distribution read since July
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Crane NXT, Co. holds its Markup at $59.29. The statistical read favours the sellers, held for 76 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 76 days
Price at the screen
$59.29
Valuation
25.78 trailing · 13.04 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.96
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
38.82%
Below 33%
Interest-bearing debt is 38.8% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
18.79%
Below 49%
Money owed to the company is 18.8% of assets, under the 49% limit.
Pass
Revenue purity
0.06%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Crane NXT,'s business is in a permissible area, but its interest-bearing debt is about 39% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CXT's ethical verdict changes
Today CXT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 23% discount to our $79.75 fair value, 22.00% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 25.7% discount to the base estimate.
Where our models see it going: fair-value estimate $79.75, with a range of $70.88 to $118.13, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Coin counters and note checkers at a discount
Every time a vending machine swallows coins or a banknote machine checks for fakes, Crane NXT sits behind the transaction. The business splits between payment hardware and security authentication tech, both areas showing 17% revenue growth and an 8% profit margin. At 10.8 times forward earnings and a 57% gap to our $80 fair value, the numbers look attractive on paper, yet the opportunity rating sits at none.
We pass because the return on equity of just 11% and unknown moat give little conviction that the discount will close. Six analysts see a median target of $66, only modestly above the current $51 price, and the ethical screen clears without adding any extra edge.
Cyclical exposure in industrial machinery adds the usual trap risk, where low multiples often mark peak earnings rather than bargains. Currency moves and customer concentration could still bite. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CXT trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup$60.04+2.5%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (6 analysts) rates it strong buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$58.60+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (6 analysts) rates it strong buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$58.60+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (6 analysts) rates it strong buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$58.60+0.5%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (6 analysts) rates it strong buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$58.29+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (6 analysts) rates it strong buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup · changed$58.29+2.5%Entry 11
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (6 analysts) rates it strong buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$56.88+1.2%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (6 analysts) rates it strong buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (6 analysts) rates it strong buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markup · changed$56.20+11.4%Entry 8
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (6 analysts) rates it strong buy, with a mean price target of $67.
2026-10-15Distribution$50.45+10.2%Entry 7
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 10.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (6 analysts) rates it strong buy, with a mean price target of $67.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
